The FDA has denied Lykos Therapeutics' marketing application for its post-traumatic stress disorder (PTSD) therapy based on MDMA, also known as ecstasy, in a setback for the emerging psychedelic ...

Multidisciplinary Association for Psychedelic Studies (MAPS), the FDA has agreed study designs for two phase 3 studies assessing MDMA-assisted psychotherapy for patients with severe PTSD.

(MENAFN- Investor Brand Network) Last week, the U.S. Food and Drug Administration (FDA) made the decision not to approve MDMA-assisted therapy for post-traumatic stress disorder. This decision ...

In teen participants, clinical trial data showed the breathing system reduced panic disorder symptom severity by 54% and PTSD symptom severity by 44%. The Food and Drug Administration (FDA ...

The FDA's review follows US Health Secretary Robert F. Kennedy Jr's recent call to end the addition of fluoride to public water systems, with Utah being the first state to do so. HealthDay News ...

SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA’s streamlined ...

US FDA Expands Use of Merck's Cancer Drug for Adrenal Gland Tumors (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to ...

Regeneron Pharmaceuticals said it is working to determine a path forward for its treatment of several retinal conditions after the Food and Drug Administration said it didn't agree with the ...

The US Food and Drug Administration (FDA) has granted marketing authorization to CT-132 (Click Therapeutics), an adjunctive, first-in-class prescription digital therapeutic for the preventive ...